Workflow
R&G PharmaStudies (301333)
icon
Search documents
诺思格声明:不实报道影响企业形象
news flash· 2025-06-19 01:30
据新浪财经消息,诺思格(301333)近日发布声明,称部分媒体及自媒体账号未经调查发布关于诺思格 及其实控人武杰的不实报道,严重影响企业形象。诺思格自2008年成立以来一直秉持科学严谨原则,但 在2020年上市申报时遭遇恶意勒索。钟大放等人通过非法手段阻碍上市进程并索要巨款,目前钟大放已 被刑拘,陈某逃往国外。诺思格谴责相关媒体歪曲事实并保留追责权利,表示正义终将得到伸张。 ...
诺思格:公司及子公司、实际控制人诉讼进展
news flash· 2025-06-18 08:06
诺思格(301333)公告,公司于近日收到最高人民法院民事申请再审案件《应诉通知书》,钟大放不服 北京市高级人民法院作出的二审民事判决,向最高人民法院提出再审。截至本公告披露日,该案件已再 审立案审查,公司将根据最终审查结果及时履行信息披露义务。 ...
诺思格(301333) - 关于公司及子公司、实际控制人诉讼进展的公告
2025-06-18 08:02
证券代码:301333 证券简称:诺思格 公告编号:2025-030 诺思格(北京)医药科技股份有限公司 关于公司及子公司、实际控制人诉讼进展的公告 一、本次诉讼的基本情况 诺思格(北京)医药科技股份有限公司(以下简称"公司")于2023年8月 收到北京市第四中级人民法院送达的《起诉状》《应诉通知书》(<2023>京04民 初142号)等诉讼材料,北京市第四中级人民法院受理原告钟大放起诉公司实际 控制人武杰(WU JIE)、公司及子公司圣兰格(北京)医药科技开发有限公司合 同纠纷一案。2024年9月,公司收到北京市第四中级人民法院做出的一审《民事 判决书》(<2023>京04民初142号)。钟大放不服一审《民事判决书》,向北京 市高级人民法院提起上诉。2025年2月,公司收到北京市高级人民法院作出的二 审民事判决书(<2024>京民终1186号),判决驳回钟大放的上诉请求,维持原判。 以上具体内容详见公司于2023年8月24日、2024年9月3日、2024年9月19日、 2025年2月18日在巨潮资讯网披露的《关于公司及子公司、实际控制人涉及诉讼 的公告》(公告编号:2023-026)及《关于公司及子公司、实 ...
巴奴向港交所提交上市申请书|首席资讯日报
首席商业评论· 2025-06-18 03:58
Group 1: Gree Electric and Shield Environment Collaboration - Gree Electric announced a collaboration with Shield Environment for a commercial energy storage project, which is not a rooftop photovoltaic project [1] - The project aims to enhance energy efficiency and facilitate green transformation in factories, reducing energy costs and serving as an emergency backup power source [1] - Gree and Shield will deeply cooperate in energy storage technology and equipment manufacturing, planning to build multiple energy projects in the Yangtze River Delta and Pearl River Delta regions [1] Group 2: Liquor Industry Insights - Guotai Junan's report indicates that the liquor industry is still in a bottoming phase in Q2 2025, with price pressures outweighing volume pressures [2] - The liquor pricing system is undergoing restructuring, with high-end liquor prices trending downward, emphasizing the strategic significance of a "full price layout" [2] - The growth logic of the liquor industry is shifting, with market share becoming more important than price/profit, leading to a competitive advantage for companies with market share [2] Group 3: Leadership Changes in Luxury Goods - Kering Group's board approved the appointment of Luca de Meo as CEO, effective September 15, 2025, following his departure from Renault [3] - The upcoming shareholders' meeting will focus on the proposal for de Meo's appointment and the approval of the new compensation policy under the new organizational structure [3] Group 4: Swine Production Adjustments - Reports indicate that the national breeding sow inventory will be reduced by approximately 1 million heads, bringing the total down to 39.5 million heads [4] Group 5: Xiaomi's Growth and Environment - Xiaomi's founder Lei Jun expressed gratitude for Beijing's favorable business environment and talent resources during the company's 15th anniversary [6] - The company has thrived in Beijing, benefiting from the local ecosystem [6] Group 6: Ba Nu International's IPO - Ba Nu International Holdings submitted an application for an IPO in Hong Kong, with adjusted net profits of RMB 76.7 million for Q1 [7] - The company reported revenues of RMB 1.433 billion, RMB 2.112 billion, and RMB 2.307 billion for the years 2022, 2023, and 2024 respectively [7] Group 7: GAC Aion's Response to Rumors - GAC Group issued a statement denying false information regarding employee stock ownership at GAC Aion, labeling it as malicious rumors [8] Group 8: Xiaomi Automotive Updates - Xiaomi Automotive clarified that there are currently no official channels for large customer orders or cash subsidies, urging the public to verify information through official sources [10] Group 9: Cao Cao Mobility's IPO Plans - Cao Cao Mobility announced plans to issue approximately 44.18 million shares through an IPO in Hong Kong, with an expected trading start date of June 25 [11] Group 10: Norse's Future Plans - Norse stated it will not independently develop innovative drugs but may consider acquiring CRO companies in the future [13] Group 11: Bitcoin Acquisition by Strategy - Strategy company acquired 10,100 bitcoins for $1.05 billion, bringing its total holdings to 592,100 bitcoins with an average cost of $70,666 per bitcoin [14]
板块持续跑赢大盘,关注后续创新药催化(附CD73靶点研究)
Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, and others [3]. Core Insights - The pharmaceutical sector has outperformed the market, with a focus on the potential of innovative drugs and the CD73 target in cancer immunotherapy [4][5]. - The report highlights the promising clinical progress of CD73 inhibitors, with several products in various stages of clinical trials [21][25]. Summary by Sections Industry Investment Rating - The report provides a list of recommended companies with "Buy" and "Hold" ratings, indicating strong investment potential in the pharmaceutical sector [3]. Industry Performance - The pharmaceutical sector rose by 1.13%, outperforming the CSI 300 index by 0.25 percentage points, with innovative drugs and vaccines leading the performance [5][32]. Company Dynamics - Companies such as Lepu Medical and Sunshine Nuohua have made significant announcements regarding new product approvals and clinical trial progress, indicating a robust pipeline and growth potential [33][34]. Industry Trends - The report discusses the increasing focus on innovative drugs and the impact of regulatory changes on the pharmaceutical landscape, suggesting a shift towards high-efficiency business models in the industry [31][40].
诺思格收盘下跌2.61%,滚动市盈率34.15倍,总市值48.92亿元
Sou Hu Cai Jing· 2025-06-05 09:51
Core Viewpoint - The company, Norsker, is experiencing a decline in stock price and has a lower PE ratio compared to the industry average, indicating potential challenges in its market position and performance [1][2]. Company Summary - Norsker's closing stock price is 50.65 yuan, down 2.61%, with a rolling PE ratio of 34.15 times and a total market capitalization of 4.892 billion yuan [1]. - The company operates in the medical services industry, which has an average PE ratio of 40.82 times and a median of 45.93 times, placing Norsker at the 24th position within the industry [1][2]. - As of the first quarter of 2025, 12 institutions hold shares in Norsker, including 7 funds and 5 other entities, with a total holding of 32.7994 million shares valued at 1.685 billion yuan [1]. Financial Performance - For the first quarter of 2025, Norsker reported revenue of 173 million yuan, a year-on-year decrease of 2.53%, while net profit was 26.0737 million yuan, reflecting a year-on-year increase of 13.12% [1]. - The company's gross profit margin stands at 36.53% [1].
诺思格: 中国国际金融股份有限公司关于诺思格(北京)医药科技股份有限公司终止部分募投项目并将剩余募集资金永久补充流动资金的核查意见
Zheng Quan Zhi Xing· 2025-06-05 09:37
Core Viewpoint - The company has decided to terminate the "Data Science Center Project" and permanently supplement the remaining raised funds into working capital due to changes in market conditions and its operational strategy [4][6][8]. Fundraising Overview - The company raised a total of RMB 1,183.2 million from its initial public offering, with a net amount of RMB 1,087.6 million after deducting issuance costs [1]. - As of April 30, 2025, the company has used RMB 578.5 million of the raised funds, leaving a balance of RMB 558.9 million [2]. Investment Project Status - The total investment for committed projects is RMB 610 million, with RMB 298.5 million already invested [2]. - The company has also allocated RMB 477.6 million for projects funded by excess raised funds, with RMB 280 million already utilized [2]. Termination of Investment Projects - The "Data Science Center Project" was intended to enhance the company's data management and statistical analysis capabilities but has been terminated due to macroeconomic factors and market demand changes [5][6]. - The remaining funds from this project, amounting to RMB 177.7 million, will be permanently added to working capital [6]. Impact on Daily Operations - The termination of the project is expected to have no adverse effects on the company's existing operations and is seen as a strategic decision to optimize fund usage [6][8]. - The decision aligns with the company's goal to improve the efficiency of fund utilization and meet daily operational funding needs [6][8]. Approval Process - The board of directors has approved the termination of the project and the reallocation of funds, which will be submitted for shareholder approval [7][8]. Sponsor's Review Opinion - The sponsor believes that the decision to terminate the project and reallocate funds is in line with the company's operational needs and will enhance the economic benefits of the raised funds [8][9].
诺思格: 第四届监事会第八次会议决议公告
Zheng Quan Zhi Xing· 2025-06-05 09:15
Group 1 - The company held its fourth supervisory board meeting on June 5, 2025, with all three supervisors present, complying with legal and regulatory requirements [1][2] - The supervisory board approved the proposal to terminate the data science center project and permanently allocate the remaining raised funds to supplement working capital, with a unanimous vote of 3 in favor [1][2] - The decision to terminate the project was made based on the company's actual situation and long-term development plan, aiming to improve the efficiency of fund utilization and align with the interests of the company and its shareholders [2]
诺思格: 关于召开2025年第一次临时股东大会通知的公告
Zheng Quan Zhi Xing· 2025-06-05 09:15
Meeting Information - The company will hold its first extraordinary general meeting of shareholders for 2025 on June 23, 2025, at 14:30, combining on-site voting and online voting [1][2] - Online voting will be available through the Shenzhen Stock Exchange trading system from 9:15 to 15:00 on the same day [1][2] Voting Rights and Attendance - All shareholders registered by the close of trading on June 17, 2025, are entitled to attend the meeting and vote [2][3] - Shareholders can appoint proxies to attend the meeting, and the proxy does not need to be a shareholder [2][3] Agenda Items - The meeting will review a proposal to terminate certain fundraising projects and permanently supplement remaining raised funds into working capital [3][6] Registration and Documentation - Individual shareholders must present their ID and proof of shareholding to attend the meeting, while corporate shareholders must provide additional documentation [3][5] - Registration can also be done via mail or fax before the deadline [4][5] Voting Procedures - The voting will be non-cumulative, allowing shareholders to express their opinions as agree, disagree, or abstain [6] - The first valid vote will be considered for any repeated voting on the same proposal [6] Contact Information - The company’s securities department can be contacted for further inquiries, with provided contact details [5][8]
诺思格(301333) - 中国国际金融股份有限公司关于诺思格(北京)医药科技股份有限公司终止部分募投项目并将剩余募集资金永久补充流动资金的核查意见
2025-06-05 09:02
中国国际金融股份有限公司 关于诺思格(北京)医药科技股份有限公司 终止部分募投项目并将剩余募集资金永久补充流动资金的核查意 见 中国国际金融股份有限公司(以下简称"中金公司"或"保荐机构")作为诺思格(北 京)医药科技股份有限公司(以下简称"诺思格"或"公司")的保荐机构,根据《证券发 行上市保荐业务管理办法》《深圳证券交易所创业板股票上市规则》《上市公司监管指 引第 2 号——上市公司募集资金管理和使用的监管要求》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管 指引第 13 号——保荐业务》等有关法律、行政法规、部门规章及业务规则的要求,对 诺思格本次终止部分募投项目并将剩余募集资金永久补充流动资金事项进行了认真、审 慎核查,具体情况如下: 一、募集资金基本情况 经中国证券监督管理委员会《关于同意诺思格(北京)医药科技股份有限公司首次 公开发行股票注册的批复》(证监许可[2022]1185 号)同意注册,公司首次公开发行人 民币普通股(A 股)股票 1,500 万股,每股面值 1.00 元,每股发行价格为人民币 78.88 元,募集资金总额为人民 ...